Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia

Archives of General Psychiatry

Volumn 69, Issue 12, 2012, Pages 1195-1204

  Nielsen, Mette Odegaard ^a   Rostrup, Egill ^a   Wulff, Sanne ^a   Bak, Nikolaj ^a   Broberg, Brian Villumsen ^a   Lublin, Henrik ^a   Kapur, Shitij ^b   Glenthoj, Birte ^a  

^a Mental Health Services CPH   (Denmark)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE;

ADULT; ANTICIPATION; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DENMARK; DRUG DOSE INCREASE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; OUTPATIENT; OXYGEN BLOOD LEVEL; REWARD; SCHIZOPHRENIA; SOCIAL STATUS; STATISTICAL ANALYSIS; TASK PERFORMANCE; UNSPECIFIED SIDE EFFECT;

EID: 84870581770     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2012.847     Document Type: Article

References (45)

1. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-1599. (Pubitemid 27120526)
2. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007;191(3):391-431. (Pubitemid 46355895)
3. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia, version III: the final common pathway. Schizophr Bull. 2009;35(3):549-562.
4. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003; 160(1):13-23. (Pubitemid 36042420)
5. Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia: psychopathological and behavioral correlates. Eur Psychiatry. 2002;17(1):9-16. (Pubitemid 34266300)
6. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009;15(22):2550-2559.
7. Juckel G, Schlagenhauf F, Koslowski M, Wüstenberg T, Villringer A, Knutson B, Wrase J, Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29(2):409-416. (Pubitemid 43063297)
8. Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A. Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry. 2009;65(12):1032-1039.
9. Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull. 2010;36(3):472-485.
10. Simon JJ, Biller A, Walther S, Roesch-Ely D, Stippich C, Weisbrod M, Kaiser S. Neural correlates of reward processing in schizophrenia: relationship to apathy and depression. Schizophr Res. 2010;118(1-3):154-161.
11. Waltz JA, Schweitzer JB, Ross TJ, Kurup PK, Salmeron BJ, Rose EJ, Gold JM, Stein EA. Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology. 2010;35(12):2427-2439.
12. Walter H, Kammerer H, Frasch K, Spitzer M, Abler B. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berl). 2009;206(1):121-132.
13. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wüstenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl). 2006;187(2):222-228. (Pubitemid 44015616)
14. Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl). 2008;196(4):673-684.
15. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369. (Pubitemid 32205190)
16. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47(1):27-38. (Pubitemid 34302921)
17. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry. 2003;160(8):1413-1420. (Pubitemid 41070915)
18. Carnoy P, Soubrie P, Puech AJ, Simon P. Performance deficit induced by low doses of dopamine agonists in rats: toward a model for approaching the neurobiology of negative schizophrenic symptomatology? Biol Psychiatry. 1986; 21(1):11-22. (Pubitemid 16043730)
19. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthøj B. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry. 2012;71(10):898-905.
20. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
21. Oldfield RC. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia. 1971;9(1):97-113.
22. Crawford JR, Besson JA, Bremner M, Ebmeier KP, Cochrane RH, Kirkwood K. Estimation of premorbid intelligence in schizophrenia. Br J Psychiatry. 1992; 161:69-74.
23. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2-3):247-265. (Pubitemid 40804771)
24. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;(22): 39-44. (Pubitemid 23355888)
25. Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, Krause D, Seemüller F. Is the PANSS used correctly? a systematic review. BMC Psychiatry. 2011;11:113.
26. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci. 2001;21(16):RC159.
27. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport. 2001;12(17):3683-3687. (Pubitemid 33105151)
28. Cooper JC, Knutson B. Valence and salience contribute to nucleus accumbens activation. Neuroimage. 2008;39(1):538-547. (Pubitemid 350102197)
29. Zink CF, Pagnoni G, Martin ME, Dhamala M, Berns GS. Human striatal response to salient nonrewarding stimuli. J Neurosci. 2003;23(22):8092-8097. (Pubitemid 37082462)
30. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. (Pubitemid 351418005)
31. Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebocontrolled fMRI study. Psychopharmacology (Berl). 2007;191(3):823-833. (Pubitemid 46355905)
32. Jocham G, Klein TA, Ullsperger M. Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices. J Neurosci. 2011;31(5):1606-1613.
33. Möller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1101-1111.
34. Menon M, Jensen J, Vitcu I, Graff-Guerrero A, Crawley A, Smith MA, Kapur S. Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry. 2007;62(7):765-772. (Pubitemid 47381433)
35. Kirsch P, Ronshausen S, Mier D, Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry. 2007;40(5):196-198. (Pubitemid 47535746)
36. Waltz JA, Schweitzer JB, Gold JM, Kurup PK, Ross TJ, Salmeron BJ, Rose EJ, McClure SM, Stein EA. Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology. 2009;34(6):1567-1577.
37. Schlagenhauf F, Rapp MA, Huys QJ, Beck A, Wüstenberg T, Deserno L, Buchholz HG, Kalbitzer J, Buchert R, Bauer M, Kienast T, Cumming P, Plotkin M, Kumakura Y, Grace AA, Dolan RJ, Heinz A. Ventral striatal prediction error signaling is associated with dopamine synthesis capacity and fluid intelligence [published online February 17, 2012]. Hum Brain Mapp. doi:10.1002/hbm.22000.
38. Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC. Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain. 2007;130(pt 9):2387-2400. (Pubitemid 47327635)
39. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry. 2008;13(3):239-276.
40. Murray GK, Corlett PR, Fletcher PC. The neural underpinnings of associative learning in health and psychosis: how can performance be preserved when brain responses are abnormal? Schizophr Bull. 2010;36(3):465-471.
41. Stoy M, Schlagenhauf F, Sterzer P, Bermpohl F, Hägele C, Suchotzki K, Schmack K, Wrase J, Ricken R, Knutson B, Adli M, Bauer M, Heinz A, Ströhle A. Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. J Psychopharmacol. 2012;26(5):677-688.
42. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119-128.
43. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol. 2010;20(3):153-163.
44. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010;49(1):1133-1143.
45. Rose EJ, Ross TJ, Salmeron BJ, Lee M, Shakleya DM, Huestis M, Stein EA. Chronic exposure to nicotine is associated with reduced reward-related activity in the striatum but not the midbrain. Biol Psychiatry. 2012;71(3):206-213.